Company: CRL
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001100682-25-000021
Chunk: 19

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-05-07
Form: 10-Q
Item: Item 1A
Chunk 19
---
 impact on our operating results or result in increased volatility in our stock price. 

Any potential transaction or other strategic alternative would be dependent on a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, regulatory approvals, and the availability of financing for a potential transaction on favorable terms. There can be no assurance that any potential transaction or other strategic alternative will be successfully implemented, achieve the intended benefits or provide greater value to our stockholders than that reflected in the current price of our common stock. Until the review process is concluded, perceived uncertainties related to our future may result in the loss of potential business opportunities, volatility in the market price of our common stock and difficulty attracting and retaining qualified talent and business partners.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information relating to the purchases of shares of our common stock during the three months ended March 29, 2025.Total Numberof SharesPurchasedAveragePrice Paidper Share (1)Total Number ofShares Purchasedas Part of PubliclyAnnounced Plansor ProgramsApproximate DollarValue of SharesThat May Yet BePurchased Underthe Plans or Programs(in thousands)December 29, 2024 to January 25, 2025235 $183.22 — $899,326 January 26, 2025 to February 22, 202518,387 165.57 — 899,326 February 23, 2025 to March 29, 20252,067,346 169.32 2,067,326 549,285 Total2,085,968  2,067,326  (1) The average price paid per share excludes $3.4 million of excise taxes incurred on share repurchases for the three months ended March 29, 2025.

On August 2, 2024, our Board of Directors has authorized, in aggregate, a stock repurchase authorization of $1 billion. During the three months ended March 29, 2025, we repurchased 2.1 million shares of common stock for $350.0 million under the new stock repurchase program. As of March 29, 2025, we had $549.3 million remaining on the authorized stock repurchase program.

Additionally, our stock-based compensation plans permit the netting of common stock upon vesting of restricted stock units, and performance share units in order to satisfy